Novel Photodepletion Strategy to Preserve and Expand Tregs While Eliminating CD4+ Effector T Cells From Patients with Chronic Graft-Versus-Host Disease

Abstract 353 Even the most potent immunosuppressive drugs often fail to control graft-versus-host disease (GVHD), the most frequent and deleterious post-transplantation adverse condition. The development of a strategy to eliminate alloreactive T cells and spare regulatory T cells (Tregs) would provi...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2010-11, Vol.116 (21), p.353-353
Main Authors: Bastien, Jean-Philippe, Krosl, Gorazd, Therien, Cynthia, Rashkovan, Marissa, Scotto, Christian, Cohen, Sandra, Allan, David S., Hogge, Donna E., Egeler, R. Maarten, Perreault, Claude, Roy, Denis-Claude
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract 353 Even the most potent immunosuppressive drugs often fail to control graft-versus-host disease (GVHD), the most frequent and deleterious post-transplantation adverse condition. The development of a strategy to eliminate alloreactive T cells and spare regulatory T cells (Tregs) would provide a direly needed therapeutic option for patients with refractory GVHD. We previously reported that photodepletion using dibromorhodamine (TH9402) eliminates T cells from healthy donors activated against major histocompatibility complex (MHC)-incompatible cells and spares resting T cells. In the present study, we identified novel photodepletion conditions (1.32 μM TH9402, 45 minutes incubation, and 5 J/cm2 light delivery at 514 nm) selectively eradicating 60–90% of endogenous proliferating host T cells as measured by 3H-thymidine incorporation, and CD4+CD25+FOXP3- effector memory phenotype cells (p
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V116.21.353.353